Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Association between myocarditis and antipsychotics other than clozapine: a systematic literature review and a pharmacovigilance study using VigiBase
Carlos De las Cuevas, Emílio J. Sanz, Christopher Rohde, et al.
Expert Review of Clinical Pharmacology (2022) Vol. 15, Iss. 1, pp. 65-78
Closed Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Reflections on the Lack of Consideration of Ethnic Ancestry to Stratify Clozapine Dosing
José de León
Psychiatry Investigation (2023) Vol. 20, Iss. 3, pp. 183-195
Open Access | Times Cited: 22
An international guideline with six personalised titration schedules for preventing myocarditis and pneumonia associated with clozapine
José de León, Can‐Jun Ruan, Georgios Schoretsanitis, et al.
General Psychiatry (2022) Vol. 35, Iss. 3, pp. e100773-e100773
Open Access | Times Cited: 29
Escaping the Long Shadow Cast by Agranulocytosis
José de León, Manuel Arrojo, Hélène Verdoux, et al.
Journal of Clinical Psychopharmacology (2023) Vol. 43, Iss. 3, pp. 239-245
Closed Access | Times Cited: 19
Adverse drug reactions and their fatal outcomes in clozapine patients in VigiBase: Comparing the top four reporting countries (US, UK, Canada and Australia)
Carlos De las Cuevas, Emílio J. Sanz, José de León
Schizophrenia Research (2023)
Open Access | Times Cited: 16
Can Slow Personalized Titration Using C-Reactive Protein Monitoring Decrease the High Rates and Mortality of Clozapine-Associated Myocarditis Seen in Some Countries? A Call for Research
José de León
Journal of Clinical Psychopharmacology (2024)
Closed Access | Times Cited: 5
High rates of myocarditis with clozapine in the Hunter region of Australia
T. N. Srinivasan, Mahinda K. Arachchi
Schizophrenia Research (2024) Vol. 264, pp. 543-548
Closed Access | Times Cited: 4
When, Why and How to Re-challenge Clozapine in Schizophrenia Following Myocarditis
Mishal Qubad, Gabriele Dupont, Martina Hahn, et al.
CNS Drugs (2024) Vol. 38, Iss. 9, pp. 671-696
Open Access | Times Cited: 4
Clozapine pharmacovigilance in Croatia: underreporting of specific adverse drug reactions and excellent reporting of suicide attempts
José de León, Marina Šagud, Emílio J. Sanz, et al.
Psychiatry Research (2025), pp. 116408-116408
Closed Access
Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part II
José de León, Ross J. Baldessarini, Richard Balon, et al.
Journal of Clinical Psychopharmacology (2025)
Closed Access
Myocarditis in patients on long-term antipsychotics –mechanism, management and recent updates
Patterson Daniel, Katta Maanya Rajaree, Rudy Luna, et al.
Heliyon (2023) Vol. 9, Iss. 3, pp. e13930-e13930
Open Access | Times Cited: 10
Respiratory aspiration during treatment with clozapine and other antipsychotics: a literature search and a pharmacovigilance study in vigibase
Carlos De las Cuevas, Emílio J. Sanz, Alejandro Villasante‐Tezanos, et al.
Expert Opinion on Drug Metabolism & Toxicology (2023) Vol. 19, Iss. 2, pp. 57-74
Open Access | Times Cited: 10
Revealing the reporting disparity: VigiBase highlights underreporting of clozapine in other Western European countries compared to the UK
Carlos De las Cuevas, Emílio J. Sanz, Jason A. Gross, et al.
Schizophrenia Research (2023) Vol. 268, pp. 175-188
Open Access | Times Cited: 10
Overcoming clozapine’s adverse events: a narrative review of systematic reviews and meta-analyses
Timothy Tanzer, Betty Pham, Nicola Warren, et al.
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 7, pp. 811-831
Closed Access | Times Cited: 3
Effects of titration speed, gender, obesity and concomitant medications on the risk and onset time of clozapine-associated fever among Japanese patients with schizophrenia: retrospective review of charts from 21 hospitals
Yuki Kikuchi, Masahiro Kurosawa, Mutsumi Sakata, et al.
The British Journal of Psychiatry (2024) Vol. 225, Iss. 5, pp. 492-498
Closed Access | Times Cited: 3
Clozapine may consistently protect from suicidal behaviors while other antipsychotics may lack a specific protective effect: a comprehensive VigiBase study interpreted in the context of the prior literature
Carlos De las Cuevas, Victoria de León-Martínez, Hilario Blasco‐Fontecilla, et al.
Expert Opinion on Drug Safety (2024), pp. 1-11
Closed Access | Times Cited: 3
Association between initial pattern of clozapine titration, concentration-to-dose ratio, and incidence of fever in patients with schizophrenia spectrum disorders in a Korean tertiary hospital
Nuree Kang, Se Hyun Kim, Jayoun Kim, et al.
Schizophrenia Research (2023)
Closed Access | Times Cited: 8
Clozapine-associated pericarditis and pancreatitis in children and adolescents: A systematic literature review and pharmacovigilance study using the VigiBase database
Renato de Filippis, Carlos De las Cuevas, Emílio J. Sanz, et al.
Schizophrenia Research (2023) Vol. 268, pp. 118-130
Open Access | Times Cited: 8
The history of clozapine in clinical practice: From its introduction to a guideline proposing personalized titrations
José de León
Journal of Psychopharmacology (2022) Vol. 36, Iss. 6, pp. 657-660
Closed Access | Times Cited: 13
Pharmacovigilance in Action: Utilizing VigiBase Data to Improve Clozapine Safety
Carlos De las Cuevas, Emílio J. Sanz, José de León
Patient Preference and Adherence (2024) Vol. Volume 18, pp. 2261-2280
Open Access | Times Cited: 2
Clozapine-induced myocarditis in children and adolescents: a pharmacovigilance study using VigiBase and a systematic literature review
Carlos De las Cuevas, Manuel Arrojo, Can‐Jun Ruan, et al.
Expert Opinion on Drug Metabolism & Toxicology (2022) Vol. 18, Iss. 11, pp. 715-727
Open Access | Times Cited: 11
The association between exposure to clozapine, olanzapine, and quetiapine and the outcomes perimyocarditis and heart failure: A population-based cohort study
Eric Clapham, Johan Reutfors, Marie Linder, et al.
Psychiatry Research (2023) Vol. 326, pp. 115336-115336
Open Access | Times Cited: 6
Precision psychiatry: The complexity of personalizing antipsychotic dosing
José de León
European Neuropsychopharmacology (2022) Vol. 58, pp. 80-85
Closed Access | Times Cited: 9
Drug-induced myocarditis: a real-world pharmacovigilance study using the FDA adverse event reporting system database
Yunxiang Zhong, Zhiping Li, Jinyi Tao, et al.
Expert Opinion on Drug Safety (2024), pp. 1-8
Closed Access | Times Cited: 1
Evaluating the adverse drug reactions to clozapine in populations of children and adolescents: insights from VigiBase data
Carlos De las Cuevas, Emílio J. Sanz, Sara Jiménez‐Fernández, et al.
European Child & Adolescent Psychiatry (2024)
Closed Access | Times Cited: 1
The cellular mechanism of antipsychotic-induced myocarditis: A systematic review
Nazanin Vaziri, Diogo Luís Marques, Steven C. Greenway, et al.
Schizophrenia Research (2023) Vol. 261, pp. 206-215
Closed Access | Times Cited: 3
Page 1 - Next Page

Scroll to top